SiteMap
Pages
- Home
- About AMD
- About LumiThera
- About Photobiomodulation
- Careers
- Cart
- Checkout
- Clinical Research
- Contact Us
- EULA
- Events
- Events
- Help
- icon.svg
- My Account Dashboard
- News & Info
- Our Products
- Privacy Policy
- SiteMap
- Store
- Subscribe
- Subscription Confirmed
- Terms and Conditions of Sale
- Terms of Use
- Thank you!
Posts by category
- Category: Articles
- A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION
- Photobiomodulation as a Treatment in Dry AMD
- The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal
- TORPA 1 and 2
- Dry AMD Therapy Evolves with Photobiomodulation
- Quantitative Analysis of Transcranial and Intraparenchymal Light Penetration in Human Cadaver Brain Tissue
- Absorption of Monochromatic and Narrow Band Radiation in the Visible and Near IR by Both Mitochondrial and Non-Mitochondrial Photoacceptors Results in Photobiomodulation
- Treatment with 670 nm Light Upregulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model
- Recharging Mitochondrial Batteries in Old Eyes. Near Infra-Red Increases ATP
- Low-Level Laser Therapy Improves Vision in a Patient with Retinitis Pigmentosa
- Photobiomodulation in the Treatment of Patients with Non-Center-Involving Diabetic Macular Oedema
- 670nm Photobiomodulation as a Novel Protection Against Retinopathy of Prematurity: Evidence from Oxygen Induced Retinopathy Models
- Increases in Central Retinal Artery Blood Flow in Humans Following Carotid Artery and Stellate Ganglion Irradiation with 0.6 to 1.6 mum Irradiation
- Gene and Noncoding RNA Regulation Underlying Photoreceptor Protection: Microarray Study of Dietary Antioxidant Saffron and Photobiomodulation in Rat Retina
- Photobiomodulation Protects the Retina from Light-Induced Photoreceptor Degeneration
- Low-Level Light Therapy of the Eye and Brain
- Mitochondrial Signal Transduction in Accelerated Wound and Retinal Healing by Near-Infrared Light Therapy
- Therapeutic Photobiomodulation for Methanol-Induced Retinal Toxicity
- Power Games
- Category: Press Releases
- LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
- LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data
- LumiThera Announces Fast Company Honors AdaptDx Pro As An Innovation and Design Award Winner
- LumiThera, Inc. Announces Purchase of MacuLogix Assets
- LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry Age-Related Macular Degeneration
- Diopsys, Inc. Announces Move to Expanded Headquarters in New Jersey
- LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects
- LumiThera Secures Financing to Support Commercial Activities
- LumiThera, Inc. Announces Completion of Diopsys, Inc. Acquisition
- LumiThera, Inc. Announces Creation of a Light-based Theranostic Approach to Treat Ocular Disease with Acquisition of Diopsys, Inc.
- LumiThera Announces Valeda Treatments Improve Vision and Retinal Function in Top Line Data from the ELECTROLIGHT Pilot Study in Dry AMD patients
- LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema
- LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD patients
- LumiThera listed as 1 of 10 Startups to Watch
- LumiThera Completes Patient Enrollment in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration
- LumiThera Announces Ryan Montecucco as General Counsel
- LumiThera and Diopsys Announce Collaboration and Enrollment of First Subject in the ELECTROLIGHT Study in Dry AMD patients
- LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema
- LumiThera Closes Series C Round of Financing
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda® Light Delivery System
- LumiThera Adds Daniel Bertholet to Board of Directors
- LumiThera Closes 2nd Tranche of Series C Financing
- LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration
- Valeda Light Delivery System Receives 2019 Medical Design Excellence Award
- LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
- LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology
- LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries
- LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
- LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
- Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe
- LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe
- LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL
- LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the European Society of Retina Specialists (EURETINA) in Vienna, Austria
- LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark
- LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
- LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
- LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco
- LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018
- LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data
- LumiThera Closes Series B Round of Financing
- LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017
- LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference
- LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016
- LumiThera Obtains Approval by Health Canada to Start Age-related Macular Degeneration Clinical Study
- LumiThera Receives Notice of Awards for two National Eye Institute Grants
- LumiThera Receives LSDF Commercialization Grant Award
- Retired Congressman Norman Dicks Joins LumiThera’s Advisory Team
- Retired Major General Gale Pollock Joins LumiThera’s Scientific Advisory Board
- Video Introduction
- LumiThera Receives Notice of LSDF Grant Award
